Abstract
Dermatomycosis are fungal infections that involve the stratum corneum of the skin and the nails, hair, and surfaces of mucous membranes. Mycological infections represent important public health disorders, and their incidence has increased in recent years. This increase may result from a number of causes, such as an increase in the susceptible population, including the elderly and immunodeficient, and social and cultural exchanges associated with sports and the use of swimming pools. In immunodeficient individuals, the lesions associated with dermatomycosis are more intense, and what are initially superficial lesions can result in disseminated and fatal forms. The primary reasons for this include antifungal resistance, toxicity, lack of rapid and specific diagnoses and the poor penetration of drugs. The currently available antifungal agents for the treatment of dermatomycosis include azole and the allylamine group of drugs. The problems related to dermatomycosis therapy are the low residence times of the dosage forms in the site of action, side effects and variable drug permeability. Thus, novel topical drug delivery systems for antifungal therapy have been developed, including liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, silver nanoparticles, microemulsion and liquid crystals. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for dermatomycosis treatment.
Keywords: Dermatomycosis, drug delivery systems, nanotechnology
Current Nanoscience
Title:Nanotechnology-based Drug Delivery Systems for Dermatomycosis Treatment
Volume: 8 Issue: 4
Author(s): Ana Luiza Ribeiro de Souza, Charlene Priscila Kiill, Fernanda Kolenyak dos Santos, Gabriela Marielli da Luz, Hilris Rocha e Silva, Marlus Chorilli and Maria Palmira Daflon Gremiao
Affiliation:
Keywords: Dermatomycosis, drug delivery systems, nanotechnology
Abstract: Dermatomycosis are fungal infections that involve the stratum corneum of the skin and the nails, hair, and surfaces of mucous membranes. Mycological infections represent important public health disorders, and their incidence has increased in recent years. This increase may result from a number of causes, such as an increase in the susceptible population, including the elderly and immunodeficient, and social and cultural exchanges associated with sports and the use of swimming pools. In immunodeficient individuals, the lesions associated with dermatomycosis are more intense, and what are initially superficial lesions can result in disseminated and fatal forms. The primary reasons for this include antifungal resistance, toxicity, lack of rapid and specific diagnoses and the poor penetration of drugs. The currently available antifungal agents for the treatment of dermatomycosis include azole and the allylamine group of drugs. The problems related to dermatomycosis therapy are the low residence times of the dosage forms in the site of action, side effects and variable drug permeability. Thus, novel topical drug delivery systems for antifungal therapy have been developed, including liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, silver nanoparticles, microemulsion and liquid crystals. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for dermatomycosis treatment.
Export Options
About this article
Cite this article as:
Luiza Ribeiro de Souza Ana, Priscila Kiill Charlene, Kolenyak dos Santos Fernanda, Marielli da Luz Gabriela, Rocha e Silva Hilris, Chorilli Marlus and Palmira Daflon Gremiao Maria, Nanotechnology-based Drug Delivery Systems for Dermatomycosis Treatment, Current Nanoscience 2012; 8 (4) . https://dx.doi.org/10.2174/157341312801784311
DOI https://dx.doi.org/10.2174/157341312801784311 |
Print ISSN 1573-4137 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6786 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polo-Like Kinases Inhibitors
Current Medicinal Chemistry Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry Pharmacologic Evidence of Green Tea in Targeting Tyrosine Kinases
Current Reviews in Clinical and Experimental Pharmacology VEGF Inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspectives
Current Clinical Pharmacology Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Interferon-α Treatment in Systemic Mastocytosis
Current Drug Targets Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents
Current Protein & Peptide Science Linezolid Activity Against Disseminated Listeria monocytogenes Meningitis and Central Nervous System Abscesses: Focus on Early Drug Myelotoxicity
Current Drug Safety Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design Recent Progress in the Identification and Clinical Evaluation of Inhibitors of the Mitotic Kinesin KSP
Current Topics in Medicinal Chemistry Netrin and DCC: Axon Guidance Regulators at the Intersection of Nervous System Development and Cancer
Current Drug Targets 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Pharmacokinetics-Guided Dosing of 5-Fluorouracil for Precision Cancer Treatment: A Focus on Colorectal Carcinoma
Applied Clinical Research, Clinical Trials and Regulatory Affairs RETRACTED: Novel and safer self-inactivating vectors for gene therapy of Wiskott-Aldrich Syndrome
Current Gene Therapy Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy
Current Pharmaceutical Design